| pubmed-article:18158962 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C1515830 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C1831743 | lld:lifeskim |
| pubmed-article:18158962 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18158962 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18158962 | pubmed:dateCreated | 2007-12-26 | lld:pubmed |
| pubmed-article:18158962 | pubmed:abstractText | Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients. High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in sustained complete remissions in selected patients with recurrent chemosensitive disease. Based on a favorable experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-HIV-associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken using the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent HIV-associated NHL and HL. Of the 27 patients in the study, 20 received an AuSCT. The median time to achievement of an absolute neutrophil count (ANC) of >or= 0.5 x 10(9)/L was 11 days (range, 9-16 days). The median time to achievement of an unsupported platelet count of >or= 20 x 10(9)/L was 13 days (range, 6-57 days). One patient died on day +33 posttransplantation from hepatic veno-occlusive disease (VOD) and multiorgan failure. No other fatal regimen-related toxicity occurred. Ten of 19 patients (53%) were in complete remission at the time of their day +100 post-AuSCT evaluation. Of the 20 patients, 10 were alive and event-free at a median of 23 weeks post-AuSCT. Median overall survival (OS) was not reached by 13 of the 20 patients alive at the time of last follow-up. This multi-institutional trial demonstrates that a regimen of dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT is well tolerated and is associated with favorable disease-free survival (DFS) and OS probabilities for selected patients with HIV-associated NHL and HL. | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18158962 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18158962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18158962 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18158962 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18158962 | pubmed:issn | 1523-6536 | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:LeeJeannette... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:ScaddenDavid... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:StrausDavid... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:AmbinderRicha... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:KaplanLawrenc... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:SpitzerThomas... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:AboulafiaDavi... | lld:pubmed |
| pubmed-article:18158962 | pubmed:author | pubmed-author:WachsmanWilli... | lld:pubmed |
| pubmed-article:18158962 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18158962 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18158962 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18158962 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18158962 | pubmed:pagination | 59-66 | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:meshHeading | pubmed-meshheading:18158962... | lld:pubmed |
| pubmed-article:18158962 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18158962 | pubmed:articleTitle | Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. | lld:pubmed |
| pubmed-article:18158962 | pubmed:affiliation | Bone Marrow Transplant Program, Massachusetts General Hospital, 0 Emerson Place, Suite 118, 55 Fruit Street, Boston, MA 02114, USA. | lld:pubmed |
| pubmed-article:18158962 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18158962 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:18158962 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:18158962 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18158962 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18158962 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18158962 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18158962 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18158962 | lld:pubmed |
